Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Age and prediction of remission and relapse of proteinuria and corticosteroid-related adverse events in adult-onset minimal-change disease: a retrospective cohort study.

Shinzawa M, Yamamoto R, Nagasawa Y, Oseto S, Mori D, Tomida K, Hayashi T, Izumi M, Fukunaga M, Yamauchi A, Tsubakihara Y, Rakugi H, Isaka Y.

Clin Exp Nephrol. 2013 Dec;17(6):839-47. doi: 10.1007/s10157-013-0793-9. Epub 2013 Mar 20.

PMID:
23512647
2.

Comparison of methylprednisolone plus prednisolone with prednisolone alone as initial treatment in adult-onset minimal change disease: a retrospective cohort study.

Shinzawa M, Yamamoto R, Nagasawa Y, Oseto S, Mori D, Tomida K, Hayashi T, Izumi M, Fukunaga M, Yamauchi A, Tsubakihara Y, Isaka Y.

Clin J Am Soc Nephrol. 2014 Jun 6;9(6):1040-8. doi: 10.2215/CJN.12331213. Epub 2014 Apr 10.

3.

Steroid responsiveness and frequency of relapse in adult-onset minimal change nephrotic syndrome.

Nakayama M, Katafuchi R, Yanase T, Ikeda K, Tanaka H, Fujimi S.

Am J Kidney Dis. 2002 Mar;39(3):503-12.

PMID:
11877569
4.

Adult-onset minimal change disease among Taiwanese: clinical features, therapeutic response, and prognosis.

Huang JJ, Hsu SC, Chen FF, Sung JM, Tseng CC, Wang MC.

Am J Nephrol. 2001 Jan-Feb;21(1):28-34.

PMID:
11275629
5.

Tacrolimus improves proteinuria remission in adults with cyclosporine A-resistant or -dependent minimal change disease.

Xu D, Gao X, Bian R, Mei C, Xu C.

Nephrology (Carlton). 2017 Mar;22(3):251-256. doi: 10.1111/nep.12991.

PMID:
28035723
6.

Minimal change nephrotic syndrome in adults: response to corticosteroid therapy and frequency of relapse.

Fujimoto S, Yamamoto Y, Hisanaga S, Morita S, Eto T, Tanaka K.

Am J Kidney Dis. 1991 Jun;17(6):687-92.

PMID:
2042651
7.

[Clinical characteristics of adult-onset minimal change nephrotic syndrome in our hospital].

Mori D, Shinzawa M, Namba T, Yamaguchi Y, Itano S, Imakita N, Matsuda J, Murata H, Takeji M, Yamamoto R, Isaka Y, Yamauchi A.

Nihon Jinzo Gakkai Shi. 2012;54(7):1023-30. Japanese.

PMID:
23234214
8.

Clinicopathologic features and treatment response in nephrotic IgA nephropathy with minimal change disease.

Qin J, Yang Q, Tang X, Chen W, Li Z, Mao H, Jiang Z, Huang F, Yu X.

Clin Nephrol. 2013 Jan;79(1):37-44. doi: 10.5414/CN107682.

PMID:
22948116
9.

Adult minimal-change disease: clinical characteristics, treatment, and outcomes.

Waldman M, Crew RJ, Valeri A, Busch J, Stokes B, Markowitz G, D'Agati V, Appel G.

Clin J Am Soc Nephrol. 2007 May;2(3):445-53. Epub 2007 Apr 11.

10.

Treatment of resistant glomerular diseases with adrenocorticotropic hormone gel: a prospective trial.

Bomback AS, Canetta PA, Beck LH Jr, Ayalon R, Radhakrishnan J, Appel GB.

Am J Nephrol. 2012;36(1):58-67. doi: 10.1159/000339287. Epub 2012 Jun 19.

PMID:
22722778
11.

Proteinuria predicts relapse in adolescent and adult minimal change disease.

Dias CB, Pinheiro CC, Silva Vdos S, Hagemann R, Barros RT, Woronik V.

Clinics (Sao Paulo). 2012 Nov;67(11):1271-4.

12.

Corticosteroid therapy in IgA nephropathy with minimal change-like lesions: a single-centre cohort study.

Wang J, Juan C, Huang Q, Zeng C, Liu Z.

Nephrol Dial Transplant. 2013 Sep;28(9):2339-45. doi: 10.1093/ndt/gft211. Epub 2013 Jun 19.

PMID:
23787555
13.

Idiopathic minimal change nephrotic syndrome in older adults: steroid responsiveness and pattern of relapses.

Tse KC, Lam MF, Yip PS, Li FK, Choy BY, Lai KN, Chan TM.

Nephrol Dial Transplant. 2003 Jul;18(7):1316-20.

PMID:
12808168
14.

Rituximab in adult patients with immunosuppressive-dependent minimal change disease.

Hoxha E, Stahl RA, Harendza S.

Clin Nephrol. 2011 Aug;76(2):151-8.

PMID:
21762648
15.

Predictors of Relapse in Adult-Onset Nephrotic Minimal Change Disease.

Lee H, Yoo KD, Oh YK, Kim DK, Oh KH, Joo KW, Kim YS, Ahn C, Han JS, Lim CS.

Medicine (Baltimore). 2016 Mar;95(12):e3179. doi: 10.1097/MD.0000000000003179.

16.

Efficacy and safety of leflunomide in treatment of steroid-dependent and steroid-resistant adult onset minimal change disease.

Zhou J, Zhang Y, Liu G, Li J, Xu R, Huang J.

Clin Nephrol. 2013 Aug;80(2):121-9. doi: 10.5414/CN107723.

PMID:
23458173
17.

Effect of long-term azathioprine administration in adults with minimal-change glomerulonephritis and nephrotic syndrome resistant to corticosteroids.

Cade R, Mars D, Privette M, Thompson R, Croker B, Peterson J, Campbell K.

Arch Intern Med. 1986 Apr;146(4):737-41.

PMID:
3963956
18.

Combined cyclosporine and prednisolone therapy in adult patients with the first relapse of minimal-change nephrotic syndrome.

Eguchi A, Takei T, Yoshida T, Tsuchiya K, Nitta K.

Nephrol Dial Transplant. 2010 Jan;25(1):124-9. doi: 10.1093/ndt/gfp422. Epub 2009 Sep 9.

PMID:
19740915
19.

Leflunomide plus oral prednisone in treatment of idiopathic membranous nephropathy: a retrospective clinical study of efficacy and safety.

Yang S, Xie L, Xue W, Yin A, Lu W.

Nephrology (Carlton). 2013 Sep;18(9):615-22. doi: 10.1111/nep.12143.

PMID:
23889815
20.

Tacrolimus therapy in adults with steroid- and cyclophosphamide-resistant nephrotic syndrome and normal or mildly reduced GFR.

Li X, Li H, Ye H, Li Q, He X, Zhang X, Chen Y, Han F, He Q, Wang H, Chen J.

Am J Kidney Dis. 2009 Jul;54(1):51-8. doi: 10.1053/j.ajkd.2009.02.018. Epub 2009 May 5.

PMID:
19406543

Supplemental Content

Support Center